Sayaka Hashimoto

Sayaka Hashimoto

Auto-generated profile, based on publicly available information

Sayaka Hashimoto

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
GBGea Beunders
Gea Beunders
EVEls Voorhoeve
Els Voorhoeve
CGChristelle Golzio
Christelle Golzio
LPLuba M. Pardo
Luba M. Pardo
JRJill A. Rosenfeld
Jill A. Rosenfeld
ESErik Sistermans
Erik Sistermans

22 May 2013 in European Journal of Human Genetics
Verified
Journal Article
Closed access
MPMichelle B Polan
Michelle B Polan
MPMatthew T Pastore
Matthew T Pastore
KSKatherine Steingass
Katherine Steingass
SHSayaka Hashimoto
Sayaka Hashimoto
DTDevon L Thrush
Devon L Thrush
KMKim L McBride
Kim L McBride

1 July 2014 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
LWLauren C. Walters-Sen
Lauren C. Walters-Sen
DTDevon Lamb Thrush
Devon Lamb Thrush
SHScott E. Hickey
Scott E. Hickey
SHSayaka Hashimoto
Sayaka Hashimoto
Shalini C. ReshmiShalini C. Reshmi
Shalini C. Reshmi
CACaroline Astbury
Caroline Astbury

1 September 2013 in Forensic Science International: Genetics
Verified
Journal Article
Closed access
ERElena A. Repnikova
Elena A. Repnikova
JRJill A. Rosenfeld
Jill A. Rosenfeld
ABAndrea Bailes
Andrea Bailes
CWCecilia Weber
Cecilia Weber
LELinda Erdman
Linda Erdman
RPRobert E. Pyatt
Robert E. Pyatt

23 March 2021 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
SASara Akhavanfard
Sara Akhavanfard
ENErik Nohr
Erik Nohr
MAMohammad AlNajjar
Mohammad AlNajjar
MHMollie Haughn
Mollie Haughn
SHSayaka Hashimoto
Sayaka Hashimoto
Shalini C. ReshmiShalini C. Reshmi
Shalini C. Reshmi
Neuroblastoma is the most common cancer in infants younger than 12 months of age, occurring with an incidence of 1 in 100,000 children. The clinical outcome of neuroblastoma ranges from spontaneous regression to treatment-resistant progression and/or metastasis, and accounts for 8–10% of childhood cancer deaths. Segmental chromosomal aberrations, as well as MYCN and ALK amplification, are among factors contributing to an unfavorable genomic profile and high-risk disease classification. Here, we describe a 5-year-old male who presented with a large right renal neuroblastoma tumor having lung and liver metastases. Fluorescence in situ hybridization analysis indicated the presence of >20 copies of the 5′ region of the ALK gene in 26% of cells examined. Subsequent copy number assessment did not confirm ALK amplification, but revealed a gain of exons 2–5 of ALK, consistent with increased copy number for the 5′ region of the ALK gene. Subsequent array analysis showed the presence of other unfavorable prognostic genomic features, including segmental gain of the 17q region and amplification of the long arm of chromosome 12 harboring CDK4 and MDM2, both reported to be poor prognostic indicators in patients with atypical clinical features in neuroblastoma. Taken together, this report illustrates the importance of careful interpretation of aberrant FISH findings and subsequent use of orthogonal methods to clarify the presence of genomic alterations to successfully determine potential treatment targets.